IP Verse

Chronic Nightly Dosing Of Lasmiditan For Migraine Prevention - EP3846810

The patent EP3846810 was granted to ELI Lilly on Oct 18, 2023. The application was originally filed on Sep 3, 2019 under application number EP19773583A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3846810

ELI LILLY
Application Number
EP19773583A
Filing Date
Sep 3, 2019
Status
Granted And Under Opposition
Sep 15, 2023
Publication Date
Oct 18, 2023
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

TEVA PHARMACEUTICALSJul 15, 2024VON KAUFFMANNADMISSIBLE

Patent Citations (3) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONWO03084949
DESCRIPTIONWO2011123654
OPPOSITIONWO2010115125

Non-Patent Literature (NPL) Citations (12) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
OPPOSITION- Anonymous, "Assessment report : RAYVOW", European medicines agency, (20220623), no. EMA/622555/2022, pages 1 - 141, XP093244111
OPPOSITION- Anonymous, "Dose-ranging Study of Oral COL-144 in Acute Migraine Treatment", ClinicalTrials.gov; NCT00883051 (accessed by the Wayback Machine), (20090910), ClinicalTrials.gov; NCT00883051 (accessed by the Wayback Machine), URL: https://web.archive.org/web/20090910220814/clinicaltrials.gov/ct2/show/NCT00883051, XP093195463
OPPOSITION- Anonymous, "International Nonproprietary Names for Pharmaceutical Substances (INN)", WHO Drug Information; Proposed INN: List 102, (20090101), vol. 23, no. 4, XP093195468
OPPOSITION- Färkkila Markus, Hans-Christoph Diener, Gilles Géraud, Jose Miguel Láinez, Jean Schoenen, Alison Pilgrim, "Lasmiditan (COL-144) a Selective 5-HT1F Agonist, is a Rapid & Effective Oral Treatment for Acute Migraine", CoLucid pharmaceuticals, inc. (accessed via the Wayback Machine), (20120514), CoLucid pharmaceuticals, inc. (accessed via the Wayback Machine), URL: https://web.archive.org/web/20120514060922/http://www.colucid.com/pdf/2010_ehmtic_ph2_oral_poster.pdf, XP093195471
OPPOSITION- Ivan Garza, Jerry W Swanson, "Prophylaxis of migraine", Neuropsychiatric Disease and Treatment, Dove Medical Press (NZ) Ltd., NZ, NZ , (20060915), vol. 2, no. 3, ISSN 1176-6328, pages 281 - 291, XP009559286
OPPOSITION- Burch J. E., Hullin R. P., "Amitriptyline pharmacokinetics a crossover study with single doses of amitriptyline and nortriptyline", Psychopharmacology, DE , (19810601), vol. 74, no. 1, doi:10.1007/BF00431754, ISSN 0033-3158, pages 35 - 42, XP093244143
OPPOSITION- Markus Färkkilä, Hans-Christoph Diener, Gilles Géraud, Miguel Láinez, Jean Schoenen, Nadja Harner, Alison Pilgrim, Uwe Reuter, "Efficacy and tolerability of lasmiditan, an oral 5-HT1F receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study", The Lancet Neurology, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL, (20120501), vol. 11, no. 5, doi:10.1016/S1474-4422(12)70047-9, ISSN 1474-4422, pages 405 - 413, XP055521638
OPPOSITION- Peter J Goadsby, Richard B Litpon And Michael D Ferrari, "Migraine - Current understanding and Treatment", N Engl. J. Med, (20020124), vol. 346, no. 4, doi:10.1056/NEJMra010917, pages 257 - 270, XP055542054
OPPOSITION- Ferrari Michel D, Färkkilä Markus, Reuter Uwe, Pilgrim Alison, Davis Charles, Krauss Martin, Diener Hans-Christoph, "Acute treatment of migraine with the selective 5-HT 1F receptor agonist lasmiditan - A randomised proof-of-concept trial", Cephalalgia, Sage Publications Ltd., GB, GB , (20101001), vol. 30, no. 10, doi:10.1177/0333102410375512, ISSN 0333-1024, pages 1170 - 1178, XP093195474
OPPOSITION- Doty Erin Gautier, Krege John H, Jin Leah, Raskin Joel, Halker Singh Rashmi B, Kalidas Kavita, "Sustained responses to lasmiditan: Results from post-hoc analyses of two Phase 3 randomized clinical trials for acute treatment of migraine", Cephalalgia, GB , (20191001), vol. 39, no. 12, doi:10.1177/0333102419859313, ISSN 0333-1024, pages 1569 - 1576, XP093244094
OPPOSITION- Lanteri-Minet Michel; Valade Dominique; Geraud Gilles; Lucas Christian; Donnet Anne, "Revised French guidelines for the diagnosis and management of migraine in adults and children", The Journal of Headache and Pain, London, UK, (20140108), vol. 15, no. 1, doi:10.1186/1129-2377-15-2, ISSN 1129-2369, pages 1 - 17, XP035495360
OPPOSITION- Jessica C Oswald, Nathaniel M Schuster, "Lasmiditan for the treatment of acute migraine: a review and potential role in clinical practice", Journal of Pain Research, Dove Medical Press, GB, GB , (20180101), Volume 11, doi:10.2147/JPR.S152216, ISSN 1178-7090, pages 2221 - 2227, XP055640840

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents